



July 19, 2018

Dr. Jasbir Makker  
Medicine  
Grand Concourse


Dear Dr. Makker:

Your protocol entitled **“Assessment of Liver Steatosis and Fibrosis Using Elastography in Patients with Type-2 Diabetes Mellitus with Normal Liver Enzymes.”** IRB # 05 10 18 04, was approved on July 19, 2018. The Informed Consent Form was also approved on the same date.

You are required to notify the Institutional Review Board, in writing, of any adverse events associated with this study. Any alterations to the protocol must be approved by the IRB prior to implementing.

An annual certification is due on **5/10/19**. To ensure compliance with the annual certification deadline, please submit by **4/1/10**. If the Institutional Review Board does not receive an annual certification by this date, the IRB will deem this study closed. **Continuation of a protocol without annual review is a violation of the Code of Federal Regulations (CFR) Title 45 Part 46.109 (e).**

Sincerely,

  
Jonathan Bella, MD  
Chair  
Institutional Review Board

JB:ed



January 31, 2019


Dr. Jasbir Makker  
Medicine  
Grand Concourse

Dear Dr. Makker:

The Spanish Informed Consent Form for your protocol entitled: **"Assessment of Liver Steatosis and Fibrosis Using Elastography in Patients with Type-2 Diabetes Mellitus with Normal Liver Enzymes."** IRB # 05 10 18 04, was approved on January 31, 2019.

An annual certification continues to be due on **5/10/19**. To ensure compliance with the annual certification deadline, please submit by **4/1/19**. If the Institutional Review Board does not receive an annual certification by this date, the IRB will deem this study closed. **Continuation of a protocol without annual review is a violation of the Code of Federal Regulations (CFR) Title 45 Part 46.109 (e).**

Sincerely,

  
Jonathan Bella, MD  
Chair  
Institutional Review Board

JB:ed